Clinical trial
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
NCT01333111 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT01333111 |
|---|---|
| Title | Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients |
| Official title | A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC-0156-0000-0009 When Used for Treatment and Prophylaxis of Bleeding Episodes in Patients With Haemophilia B |
| Acronym | paradigm™ 2 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia B |
| Intervention type | Drug |
| Interventions | nonacog beta pegol |
| Enrollment | 74 |
| Start date | Apr 27, 2011 |
| Primary completion | Mar 31, 2013 |
| Completion | Mar 31, 2013 |
| First posted | Apr 11, 2011 |
| Last update posted | Jul 28, 2017 |
| Countries | Canada, France, Germany, Hungary, Italy, Japan, Malaysia, Netherlands, North Macedonia, Russia, South Africa, Thailand and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: